Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iron
Drug ID BADD_D01197
Description A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
Indications and Usage Used in preventing and treating iron-deficiency anemia.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB01592
KEGG ID Not Available
MeSH ID D007501
PubChem ID 23925
TTD Drug ID D0Y3TM
NDC Product Code 0220-2054; 62106-5042; 68428-383; 64117-791; 0220-2051; 0164-1152
UNII E1UOL152H7
Synonyms Iron | Iron-56 | Iron 56
Chemical Information
Molecular Formula Fe
CAS Registry Number 7439-89-6
SMILES [Fe]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Foaming at mouth07.05.05.019; 08.01.03.070; 17.02.05.056---
Skin plaque23.03.03.044---
Lip pruritus07.05.05.021---
Poor feeding infant14.03.02.022; 18.04.06.006---
Pharyngeal paraesthesia17.02.06.035; 22.04.05.018---
Administration site bruise08.02.04.016; 12.07.04.016; 23.03.11.023; 24.07.06.025---
Administration site induration08.02.04.022; 12.07.04.022---
Administration site pain08.02.04.029; 12.07.04.029---
Agonal respiration02.11.05.001; 22.02.01.033---
Fear of injection19.06.03.016---
Fishbane reaction08.06.01.039; 15.03.04.020---
Gait inability08.01.02.011; 17.02.05.0690.000453%-
Heavy menstrual bleeding21.01.03.0050.001904%-
Infusion related hypersensitivity reaction10.01.03.058; 12.02.05.055---
Infusion site discolouration08.02.05.026; 12.07.05.026; 23.03.03.084---
Injection site nerve damage08.02.03.066; 12.07.03.066---
Intermenstrual bleeding21.01.01.0150.002312%-
Loss of therapeutic response08.06.01.041---
Periorbital swelling06.08.03.032; 10.01.05.025; 23.04.01.025---
Sensitive skin23.03.03.097---
Similar reaction on previous exposure to drug08.06.01.046---
Swelling of eyelid06.04.04.018; 10.01.05.026; 23.04.01.026---
Therapeutic product effect delayed08.06.01.051---
Therapeutic product effect incomplete08.06.01.0520.000453%-
Therapy non-responder08.06.01.0630.000680%-
Brain fog16.32.03.050; 17.02.05.077; 19.21.02.017---
The 14th Page    First    Pre   14    Total 14 Pages